CHI3L1 and metabolic dysfunction-associated steatotic liver disease: First, to assess the feasibility of YKL-40 as a biomarker of fibrosis in NAFLD patients (Table 1), we measured serum YKL-40 levels and other fibrosis markers such as type IV collagen 7s, hyaluronic acid, WFA+ -M2BP and clinically accepted fibrosis scores (AST-to-platelet ratio index (APRI) and FIB4-index).